The new chelating P,S-ligands 2,3,4,6-tetra- O -acetyl-1-((2-(diphenylphosphino)benzy)lthio)-β- d -glucopyranose, [(2-Ph 2 PC 6 H 4 CH 2 )SCHCH(OAc)CH(OAc)CH(OAc)CH(CH 2 OAc)O, 2 ] and 2,3,4,6-tetra- O -acetyl-1-((2-(dicyclohexylphosphino)benzyl)thio)-β- d -glucopyranose [(2-Cy 2 PC 6 H 4 CH 2 )SCHCH(OAc)CH(OAc)CH(OAc)CH(CH 2 OAc)O,, 3 ] as well as their (1,3-diphenylallyl)palladium(II) cationic complexes [Pd(η 3 -PhCHCHCHPh)( 2 )]PF 6, 6, and [Pd(η 3 -PhCHCHCHPh)( 3 )]PF 6, 7, and one η 3 -C 3 H 5 complex [Pd(η 3 -C 3 H 5 )( 2 )]PF 6, 5, have been prepared. The solid-state structure of [Pd(η 3 -C 3 H 5 )( 2 )]PF 6, 5, has been determined by X-ray diffraction methods and found to have the S -sugar substituent and one of the P -phenyl rings in pseudo-axial positions on the same side of the P−Pd−S coordination plane. Detailed NMR measurements for 6 reveal the presence of two diastereomeric isomers whereas for 7 four diastereomers are found. 2-D exchange NMR is used to characterize several of the selective equilibria within 6 and 7 . On the basis of the observed ee in the enantioselective homogeneous allylic alkylation of 7, it is suggested that the reaction kinetics for the four isomers are not all the same.
No takes yet. Share an insight, caveat, or question.
Barbaro et al. (1996) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: